Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820116 | 0.93 | GABRA1 (0.31) | KCNH2 | |
| SCHEMBL820424 | 0.91 | KCNH2 (0.38) | KCNH2ALDH1A1HPGDLPLLIPG | |
| SCHEMBL27697527 | 0.89 | LOXL2 (0.32) | — | |
| SCHEMBL1778018 | 0.87 | KCNH2 (0.48) | KCNH2KDM4EALDH1A1LPLLIPG | |
| SCHEMBL818858 | 0.85 | GABRA1 (0.30) | — | |
| SCHEMBL185419 | 0.84 | KCNH2 (0.40) | KCNH2ALDH1A1HPGDLPLLIPG | |
| SCHEMBL2698334 | 0.84 | — | — | |
| SCHEMBL16439959 | 0.84 | GABRA1 (0.33) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL16439955 | 0.84 | — | — | |
| SCHEMBL28320902 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344291-A | Method for preparing imide by rearrangement of isoamide and application thereof | 中国石油化工股份有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024037146-A1 | ELECTROLYTE SOLUTION AND BATTERY | 珠海冠宇电池股份有限公司 | 2024-02-22 | — | — | WO | claimed |
| EP-4148041-B1 | SPACERED UREA (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2023-11-01 | — | — | EP | claimed |
| EP-4148040-B1 | ONE POT SYNTHESIS OF UREA (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3550657-B1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO LTD (CN) | 2023-06-28 | — | — | EP | claimed |
| US-20230101100-A1 | One Pot Synthesis of Urea (Meth)Acrylates | EVONIK OPERATIONS GMBH (DE) | 2023-03-30 | — | — | US | claimed |
| US-20230088931-A1 | Spacered Urea (Meth)Acrylates | EVONIK OPERATIONS GMBH (DE) | 2023-03-23 | — | — | US | claimed |
| EP-4148041-A1 | SPACERED UREA (METH)ACRYLATES | Evonik Operations GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | claimed |
| CN-1403424-A | Cobalt catalyst composition for ethylene oligomerization and preparation method of alpha-olefin | CHINA NAT PETROLEUM CORP (CN) | 2003-03-19 | — | — | CN | claimed |
| EP-1042278-B1 | 1,3-DISUBSTITUTED UREAS AS ACAT INHIBITORS, AND METHOD OF PREPARING THEREOF | SLOVAKOFARMA AS (SK) | 2003-03-05 | — | — | EP | claimed |
| CN-1374281-A | Iron-based catalyst composition for ethylene oligomerization and preparation method of alpha-olefin | CHINA PETROLEUM CORP (CN) | 2002-10-16 | — | — | CN | claimed |
| US-6444691-B1 | ANTICHOLESTEROL AGENTS | SOLVAKOFARMA, A.S. (SK) | 2002-09-03 | — | — | US | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1042278-A1 | 1,3-DISUBSTITUTED UREAS AS ACAT INHIBITORS, AND METHOD OF PREPARING THEREOF | Slovakofarma, A.S. (SK) | 2000-10-11 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1999032437-A1 | 1,3-DISUBSTITUTED UREAS AS ACAT INHIBITORS, AND METHOD OF PREPARING THEREOF | SLOVAKOFARMA, A.S. (SK) | 1999-07-01 | — | — | WO | claimed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | KCNH2 722/4885KDM4E 1722/4885ALDH1A1 4484/4885 |
| US-20230101100-A1 | One Pot Synthesis of Urea (Meth)Acrylates | ADH1A, ADH1C, METTL14 | KCNH2 2904/4885KDM4E 1350/4885ALDH1A1 56/4885 |
| US-20230088931-A1 | Spacered Urea (Meth)Acrylates | METTL14, METTL3, FUS | KCNH2 3941/4885KDM4E 821/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.